E‐cadherin and β‐catenin expression patterns in malignant melanoma assessed by image analysis

Abstract

Središnja medicinska knjižnicaPećina-Šlaus, N., Žigmund, M., Kušec, V., Nikuševa Martić, T., Čačić, M., AbstractBackground. We investigated the expression of E-cadherin and beta-catenin in

Caveolin-1 in Melanoma Progression

“…Specifically, mutations in -catenin have been detected in both melanoma biopsies and melanoma cell lines (Larue and Delmas 2006). These findings are reinforced by immuno-histochemical studies showing that -catenin staining is frequently observed in primary melanomas, but is less abundant in metastatic melanomas (Pecina-Slaus, Zigmund et al 2007;De Panfilis, Ferrari et al 2009) and appears to be inversely correlated with the Clark stage (Pecina-Slaus, Zigmund et al 2007). In both cases, -catenin is observed predominantly at the cell membrane and in the cytoplasm (PecinaSlaus, Zigmund et al 2007;Tucci, Lucarini et al 2007;De Panfilis, Ferrari et al 2009).…”

Phosphorylation of β-catenin results in lack of β-catenin signaling in melanoma

“…We could clearly demonstrate that β-catenin is mainly distributed in the cytoplasm of melanoma cells in vivo and under culture conditions. Studies of Maelandsmo et al and Pecina-Slaus et al support this finding (21,30). In only 5.6 or 6.4%, respectively, of the analyzed samples nuclear localization of β-catenin was observed by immunohistochemistry.…”

“…Cell lysate (5-40 µg) was separated on 10% SDS-PAGE gels and subsequently blotted onto a PvDF membrane. After blocking with 3% BSA/PBS the membrane was incubated for 16 h with one of the following antibodies: anti-β-catenin (1 in 3000 dilution) (Sigma), antihypophosphorylated β-catenin (35-50) (1 in 200 dilution) (Acris, Hiddenhausen, Germany), anti-hypophosphorylated β-catenin (27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37) (1 in 200 dilution) (upstate), anti-β-cateninphospho 41/45 (1 in 500 dilution) (Cell Signaling), anti-β-catenin phospho S33 (1 in 500 dilution), anti-β-catenin phospho S37 (1 in 500 dilution), anti-β-catenin phospho T41 (1 in 500 dilution), anti-β-catenin phospho S45 (1 in 500 dilution), (Abcam, Cambridge, UK), and anti-β-actin (1 in 5000 dilution) (Sigma).…”

Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights

“…In consistence with the observation, cytoplasmic/nuclear β-catenin expression has been reported to be reduced upon progression 47,48,[67][68][69] . However, in the individual studies, the limited sample size and potentially biased patients' selection failed to satisfy the minimal REporting recommendations for tumour MARKer prognostic studies (REMARK) guidelines 70 .…”